Company / FCF Margin
CytomX Therapeutics, Inc. FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-99.5%
FY2025
5-year range
-323.3% / -56.2%
FY2021-FY2025
Trend
-58.8%
vs FY2024
Sector context
#88 of 134
Health Care
What the data says
At -99.5%, CytomX Therapeutics, Inc.'s fcf margin ranks #88 of 134 in the Health Care sector. FCF Margin has fluctuated over the past 10 years, ranging from -323.3% in FY2021 to 235.7% in FY2017.
Based on SEC 10-K filings.
-99.5% in FY2025 with a 5-year CAGR of -102.4%.
Declined from -56.2% to -99.5% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +112.2pp
- 5-Year Change
- -102.4pp
- 10-Year Change
- -
Sector benchmark
#88 of 134 in Health CareTop 66% of 134This company -99.5% Sector average -637.8%
▼
+84.4% above sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 58.8% year-over-year.
- Currently 538.3pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2017.
- Lowest fcf margin in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -99.5% | -58.8% |
| FY2024 | -62.7% | -11.5% |
| FY2023 | -56.2% | +73.5% |
| FY2022 | -211.7% | +34.5% |
| FY2021 | -323.3% | -11097.6% |
| FY2020 | 2.9% | +101.2% |
| FY2019 | -250.4% | -87.9% |
| FY2018 | -133.3% | -156.6% |
| FY2017 | 235.7% | +942.7% |
| FY2016 | -28.0% | +97.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026